To evaluate the efficacy and safety of combination therapy of eltrombopag, recombinant human thrombopoietin (rhTPO), and standard immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This evidence concerns the gene THPO and idiopathic aplastic anemia.